secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001558370-23-016852
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts IND for Mustang Bio's MB-109 combo therapy for recurrent glioblastoma
--------------------------------------------------------------------------------

- IND accepted within 30 days of submission for MB-109 (MB-101 CAR-T + MB-108 oncolytic virus).
- Phase 1 trial to start 2024; will test safety, tolerability, efficacy in recurrent GBM and high-grade astrocytoma.
- Prior MB-101 alone saw complete responses lasting 7.5 and 31+ months in patients with hot tumors.
- Study to enroll at City of Hope and University of Alabama at Birmingham.
- Median overall survival for recurrent GBM is 6 months; combo aims to improve outcomes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023016852/0001558370-23-016852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023016852/tmb-20231026x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer